Pfizer
PFE
3,158 hedge funds and large institutions have $201B invested in Pfizer in 2022 Q2 according to their latest regulatory filings, with 130 funds opening new positions, 1,402 increasing their positions, 1,264 reducing their positions, and 122 closing their positions.
52% more funds holding in top 10
Funds holding in top 10: 166 → 252 (+86)
11% more repeat investments, than reductions
Existing positions increased: 1,402 | Existing positions reduced: 1,264
1.54% more ownership
Funds ownership: 67.24% → 68.78% (+1.5%)
7% more first-time investments, than exits
New positions opened: 130 | Existing positions closed: 122
3% more capital invested
Capital invested by funds: $196B → $201B (+$5.05B)
1% more call options, than puts
Call options by funds: $2.9B | Put options by funds: $2.89B
1% less funds holding
Funds holding: 3,196 → 3,158 (-38)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.54B |
| 2 |
BlackRock
New York
|
+$1.38B |
| 3 |
Morgan Stanley
New York
|
+$1.28B |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$556M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$478M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$355M |
| 2 |
Renaissance Technologies
New York
|
-$311M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$295M |
| 4 |
Barclays
London,
United Kingdom
|
-$210M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$193M |
PFE Hedge Fund Activity: Q2 2022 in Review
3,158 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2022, worth a combined $201B — up 2.6% from $196B a quarter earlier.
Buyers outnumbered sellers: 130 funds opened new PFE positions and 122 closed out — a net gain of 8 holders — while 1,402 added to existing stakes and 1,264 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.54B. The largest seller was D.E. Shaw & Co, cutting an estimated $355M.
- 3,158 institutional investors held Pfizer (PFE) as of Q2 2022, down from 3,196 in Q1 2022.
- Funds reported $201B of Pfizer stock for Q2 2022, up 2.6% quarter-over-quarter.
- 130 funds opened new Pfizer positions in Q2 2022 and 122 closed out, a net change of +8 holders.
- The largest Pfizer buyer in Q2 2022 was Capital World Investors, an estimated $1.54B added.
- The largest Pfizer seller in Q2 2022 was D.E. Shaw & Co, an estimated $355M sold.
Based on aggregated 13F filings for Q2 2022.